Event-Driven Stocks

UroGen Pharma Ltd.

URGNNasdaq

Healthcare · Pharmaceutical Preparations · L3 · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 3 good● 5 warning● 2 severedetails ↓

Financials

SEC XBRL · annual
 FY25FY24FY23FY22FY21FY20
Revenue$109.8M$90.4M$17.2M$64.4M$48.0M$11.8M
Operating income−$124.9M−$96.8M−$65.5M−$79.0M−$92.3M−$126.7M
Net income−$153.5M−$126.9M−$30.2M−$109.8M−$110.8M−$128.5M
Total assets$200.5M$285.7M$178.3M$135.6M$119.7M$122.0M
Total liabilities$305.9M$294.5M$243.5M$225.0M$111.3M$25.6M
Equity−$105.5M−$8.8M−$65.2M−$89.4M$8.4M$96.4M
EPS (diluted)$-3.19$-2.96$-1.30$-4.81$-4.96—
Shares out.46.1M34.1M23.4M22.7M22.3M21.2M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2025
Operating margin
−113.7%
Net margin
−139.8%
Return on equity
145.5%
Return on assets
−76.6%
Return on capital (ROCE)
−81.1%
Liabilities / assets
152.6%
Debt / equity
—
Book value / share
$-2.29
Revenue growth (YoY)
21.4%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2025
Altman Z″ (distress)
-15.59distress
Accruals / assets
4.5%clean
Beneish M-Score
-1.43elevated
Piotroski F-Score
1/9weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
49
/ 100
Profitability 20Growth 100Catalyst 67Earnings quality 33Financial strength 25

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 2 severe● 5 warning● 3 good
  • Negative shareholder equity
  • Altman Z″ in the distress zone
  • Operating losses (negative operating margin)
  • Reported a net loss
  • High leverage (liabilities > 70% of assets)
  • Negative operating cash flow
  • Beneish M-Score elevated — earnings-manipulation screen flag
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

FDA-approved drugs

openFDA · most recent
  • ZUSDURIJun 12, 2025
  • JELMYTOApr 15, 2020

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Insider transactions

SEC Form 4 · most recent
1 acquisitions0 disposalsnet +5,500 shares · last 1
InsiderDateTypeSharesPrice
Smith Jason DrewOfficer — General CounselJan 31, 2026Option exercise5,500—

Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
May 15, 20266.8M5.8-6.5%
Apr 30, 20267.2M8.9-7.5%
Apr 15, 20267.8M11.2-6.3%
Mar 31, 20268.3M11.8-3.3%
Mar 13, 20268.6M7.8+7.6%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)